 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 1 | 0 | 1 | | 1981 | 2 | 0 | 2 | | 1986 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1994 | 0 | 1 | 1 | | 1995 | 2 | 0 | 2 | | 1996 | 4 | 0 | 4 | | 1997 | 0 | 1 | 1 | | 1998 | 3 | 0 | 3 | | 1999 | 0 | 1 | 1 | | 2000 | 2 | 3 | 5 | | 2001 | 2 | 2 | 4 | | 2002 | 1 | 1 | 2 | | 2003 | 8 | 2 | 10 | | 2004 | 8 | 2 | 10 | | 2005 | 8 | 3 | 11 | | 2006 | 12 | 4 | 16 | | 2007 | 5 | 9 | 14 | | 2008 | 11 | 8 | 19 | | 2009 | 12 | 2 | 14 | | 2010 | 15 | 12 | 27 | | 2011 | 10 | 5 | 15 | | 2012 | 11 | 7 | 18 | | 2013 | 9 | 9 | 18 | | 2014 | 16 | 8 | 24 | | 2015 | 10 | 6 | 16 | | 2016 | 7 | 6 | 13 | | 2017 | 5 | 4 | 9 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 07 04; 134(1):59-73.
-
Pederson T. Nuclear Bodies Toward Human Bodies. FASEB J. 2018 11; 32(11):5761-5763.
-
Wong KE, Mora MC, Sultana N, Moriarty KP, Arenas RB, Yadava N, Schneider SS, Tirabassi MV. Evaluation of Rhodiola crenulata on growth and metabolism of NB-1691, an MYCN-amplified neuroblastoma cell line. Tumour Biol. 2018 Jun; 40(6):1010428318779515.
-
Wei XX, Ko EC, Ryan CJ. Treatment strategies in low-volume metastatic castration-resistant prostate cancer. Curr Opin Urol. 2017 Nov; 27(6):596-603.
-
Brown CW, Amante JJ, Goel HL, Mercurio AM. The a6ß4 integrin promotes resistance to ferroptosis. J Cell Biol. 2017 12 04; 216(12):4287-4297.
-
de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, Mancias JD, Callery MP, Mahadevan A, Tseng JF. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer. 2017 Nov 01; 123(21):4158-4167.
-
Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE, Vittori S, Reyes JM, di Iulio J, Souza A, Ott CJ, Roberts JM, Zeid R, Scott TG, Paulk J, Lachance K, Olson CM, Dastjerdi S, Bauer S, Lin CY, Gray NS, Kelliher MA, Churchman LS, Bradner JE. BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Mol Cell. 2017 Jul 06; 67(1):5-18.e19.
-
Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Am J Hematol. 2017 Aug; 92(8):E146-E152.
-
Tabatabaie O, Kasumova GG, Kent TS, Eskander MF, Fadayomi AB, Ng SC, Critchlow JF, Tawa NE, Tseng JF. Upper extremity deep venous thrombosis after port insertion: What are the risk factors? Surgery. 2017 08; 162(2):437-444.
-
Fiorentino M, Gruppioni E, Massari F, Giunchi F, Altimari A, Ciccarese C, Bimbatti D, Scarpa A, Iacovelli R, Porta C, Virinder S, Tortora G, Artibani W, Schiavina R, Ardizzoni A, Brunelli M, Knuutila S, Martignoni G. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. Oncotarget. 2017 Jan 31; 8(5):7328-7335.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|